Roivant Sciences Ltd. bought $350.0M of Immunovant (IMVT)
Executed Dec 12 2025, disclosed Dec 12 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Dec 12 2025), the stock returned +5.1% (delay-adjusted); from the execution session (Dec 12 2025), +5.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Roivant Sciences Ltd. (Director) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Immunovant, Inc. (IMVT). Across 1 priced purchase filing, the average 21-session return was +5.1% from execution and +5.1% from disclosure (delay-adjusted; derived). The largest single filing was $350.0M of IMVT (16,666,666 sh × $21.00, as filed), executed Dec 12 2025.
Healthcare · Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→16,845,010 sh × $20.00
Exec Jan 13 2025
Filed Jan 15 2025 · 5:30 PM ET